Addex Therapeutics Ltd

SWX:ADXN Stock Report

Market Cap: CHF 5.9m

Addex Therapeutics Management

Management criteria checks 2/4

Addex Therapeutics' CEO is Tim Dyer, appointed in Jan 2002, has a tenure of 22.83 years. directly owns 9.41% of the company’s shares, worth CHF553.09K. The average tenure of the management team and the board of directors is 7.7 years and 9.4 years respectively.

Key information

Tim Dyer

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure22.8yrs
CEO ownership9.4%
Management average tenure7.7yrs
Board average tenure9.4yrs

Recent management updates

Increases to CEO Compensation Might Be Put On Hold For Now at Addex Therapeutics Ltd (VTX:ADXN)

Jun 10
Increases to CEO Compensation Might Be Put On Hold For Now at Addex Therapeutics Ltd (VTX:ADXN)

Recent updates

Here's Why Addex Therapeutics (VTX:ADXN) Must Use Its Cash Wisely

Mar 03
Here's Why Addex Therapeutics (VTX:ADXN) Must Use Its Cash Wisely

Here's Why Addex Therapeutics (VTX:ADXN) Must Use Its Cash Wisely

May 11
Here's Why Addex Therapeutics (VTX:ADXN) Must Use Its Cash Wisely

Is Addex Therapeutics (VTX:ADXN) In A Good Position To Invest In Growth?

Nov 23
Is Addex Therapeutics (VTX:ADXN) In A Good Position To Invest In Growth?

Increases to CEO Compensation Might Be Put On Hold For Now at Addex Therapeutics Ltd (VTX:ADXN)

Jun 10
Increases to CEO Compensation Might Be Put On Hold For Now at Addex Therapeutics Ltd (VTX:ADXN)

CEO Compensation Analysis

How has Tim Dyer's remuneration changed compared to Addex Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

-CHF 12m

Mar 31 2024n/an/a

-CHF 11m

Dec 31 2023n/an/a

-CHF 11m

Sep 30 2023n/an/a

-CHF 7m

Jun 30 2023n/an/a

-CHF 9m

Mar 31 2023n/an/a

-CHF 15m

Dec 31 2022n/an/a

-CHF 21m

Sep 30 2022n/an/a

-CHF 22m

Jun 30 2022n/an/a

-CHF 21m

Mar 31 2022n/an/a

-CHF 19m

Dec 31 2021n/an/a

-CHF 15m

Sep 30 2021n/an/a

-CHF 13m

Jun 30 2021n/an/a

-CHF 13m

Mar 31 2021n/an/a

-CHF 11m

Dec 31 2020CHF 917kCHF 454k

-CHF 13m

Sep 30 2020n/an/a

-CHF 14m

Jun 30 2020n/an/a

-CHF 15m

Mar 31 2020n/an/a

-CHF 16m

Dec 31 2019CHF 709kCHF 429k

-CHF 15m

Sep 30 2019n/an/a

-CHF 13m

Jun 30 2019n/an/a

-CHF 12m

Mar 31 2019n/an/a

-CHF 6m

Dec 31 2018CHF 2mn/a

-CHF 2m

Compensation vs Market: Insufficient data to establish whether Tim's total compensation is reasonable compared to companies of similar size in the Swiss market.

Compensation vs Earnings: Tim's compensation has increased whilst the company is unprofitable.

CEO

Tim Dyer (56 yo)

22.8yrs

Tenure

Mr. Timothy Mark Dyer, also known as Tim, has been Chief Executive Officer at Addex Therapeutics Ltd. since June 1, 2013. Mr. Dyer co-founded Addex Therapeutics Ltd.(also known as Addex Pharmaceuticals Lt...

Leadership Team

NamePositionTenureCompensationOwnership
Timothy Dyer
Co-Founder22.8yrsno data9.41%
CHF 553.1k
Roger Mills
Chief Medical Officer & Director8yrsno datano data
Lénaic Teyssédou
Head of Finance7.4yrsno datano data
Mikhail Kalinichev
Head of Translational Science3.3yrsno datano data

7.7yrs

Average Tenure

56.5yo

Average Age

Experienced Management: ADXN's management team is seasoned and experienced (7.7 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Timothy Dyer
Co-Founder9.8yrsno data9.41%
CHF 553.1k
Roger Mills
Chief Medical Officer & Director7.8yrsno datano data
Isaac Manke
Independent Director6.4yrsCHF 41.29kno data
Raymond Hill
Non-Executive Director9.4yrsCHF 89.65k1.39%
CHF 81.7k
Vincent Lawton
Independent Chairman of the Board15.6yrsCHF 155.75k2.55%
CHF 150.0k

9.4yrs

Average Tenure

67yo

Average Age

Experienced Board: ADXN's board of directors are considered experienced (9.4 years average tenure).